{"id":"F2018L01280","name":"Medical Device Standards Order (Endotoxin Requirements for Medical Devices) 2018","slug":"medical-device-standards-order-endotoxin-requirements-for-medical-devices-2018","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":97979,"registerId":"commonwealth-F2018L01280-current","compilationNumber":null,"startDate":"2026-04-02","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Medical Device Standards Order (Endotoxin Requirements for Medical Devices) 2018","content":"![](image.001.png)\n\nMedical Device Standards Order (Endotoxin Requirements for Medical Devices) 2018\n\nTherapeutic Goods Act 1989\n\nI, Elizabeth McGrath, delegate of the Minister for Health for the purposes of section 41CB of the Therapeutic Goods Act 1989 and acting under that section, HEREBY DETERMINE:\n\n    (1) that the matters specified in sections 6 and 7 of this Order constitute a medical device standard for the kinds of medical devices identified in section 5 of this Order; and\n\n    (2) that medical devices of those kinds that comply with sections 6 and 7 of this Order are to be treated as complying with Clause 7.2 of the essential principles set out in Schedule 1 to the Therapeutic Goods (Medical Devices) Regulations 2002, in relation to minimising the risks associated with endotoxin contaminants and residues in or on medical devices.\n\nDated this 7th day of September 2018\n\n(Signed by)\n\nElizabeth McGrath\n\nDelegate of the Minister for Health\n\n  \n\n1 Name of Order\n\nThis Order is the Medical Device Standards Order (Endotoxin Requirements for Medical Devices) 2018.\n\n2 Commencement\n\nThis Order commences on the day after it is registered on the Federal Register of Legislation.\n\n3 Authority\n\nThis Order is made under subsection 41CB (1) of the Therapeutic Goods Act 1989 (the Act).\n\n4 Definitions\n\nIn this Order:\n\nAct means the Therapeutic Goods Act 1989.\n\ndefault standard has the same meaning as in the Act.\n\nendotoxin is the high molecular weight lipopolysaccharide component of the outer cell wall of gram-negative bacteria, which is usually a fever-inducing contaminant in the manufacturing process of medical devices.\n\nfinal product medical device or medical device component that has been subjected to all manufacturing processes for the ‘to be marketed’ medical device including packaging and if applicable, sterilisation.\n\nlabel has the same meaning as in the Act.\n\nmanufacturer has the same meaning as in section 41BG of the Act.\n\nmedical device has the same meaning as in section 41BD of the Act.\n\nRegulations means the Therapeutic Goods (Medical Devices) Regulations 2002, as in force from time to time.\n\n5 Application\n\nThis Order constitutes a medical device standard for any of the following kinds of medical devices:\n\n    (a) implantable medical devices;\n    (b) devices in direct or indirect contact with a person’s cardiovascular system, the lymphatic system, or cerebrospinal fluid that are labelled sterile and non-pyrogenic. These include, but are not limited to:\n\n    fluid pathways of catheters and administration sets such as solution administration sets, extension sets, transfer sets, blood and blood products administration sets, intravenous catheters, extracorporeal oxygenator tubing, dialysis tubing, intramuscular drug delivery catheters, transfusion and infusion assemblies, and epidural catheters;\n    liquid medical devices such as dialysate; and\n    implantable medical devices such as heart valves, vascular grafts, and cerebral spinal fluid shunt systems;\n\n    (c) devices in direct or indirect contact with a person’s intraocular environment. These include but are not limited to:\n\n    intraocular fluids such as ophthalmic viscosurgical devices including viscoelastic surgical aids;\n    implantable intraocular solid devices such as intraocular lenses, implantable miniature telescope, and iris reconstruction lenses;\n    glaucoma devices such as aqueous shunts and intraocular pressure lowering implants;\n    capsular tension ring devices; and\n    accessories of irrigation/aspiration sleeves and tubing used in the intraocular environment; or\n\n    (d) any other devices labelled sterile and non-pyrogenic.\n\n6 Bacterial endotoxin content\n\n(1) For medical devices other than those mentioned in subsection (2), the endotoxin limits for the final product must be:\n\n    (a) not more than 20 Endotoxin Units per device; or\n    (b) not more than 2.15 Endotoxin Units per device, if the device is in contact with a person’s cerebrospinal fluid.\n    (2) For medical devices in direct or indirect contact with a person’s intraocular environment, the endotoxin limits must unless a higher number of Endotoxin Units is justified be:\n    (a) not more than 0.2 Endotoxin Units per device for the anterior segment solid device; and\n    (b) not more than 0.2 Endotoxin Units per Millilitre for the ophthalmic viscosurgical device.\n\n(3) Where multiple components are assembled into the final product, the cumulative endotoxin content of each individual component must not exceed the overall threshold limit for the final product, as set out in subsections (1) or (2), except where this is justified for a medical device that is included in subsection (2).\n\n7 Bacterial endotoxin testing\n\n    (1) The medical device must be tested using Bacterial Endotoxin Test methodology of a default standard, or if applicable, an alternative method that is validated.\n    (2) If an alternative method is used, the manufacturer of the medical device must provide a scientifically sound justification for doing so, and validation evidence for the suitability of the use of that alternative test method in relation to the device.\n    (3) Testing must be conducted on every batch, except if this is not practical.\n    (4) If testing every batch is not practical, the manufacturer of the medical device must:\n    (a) establish an appropriate sampling plan and test for incoming raw materials, in-process materials and representative products to ensure that the manufacturing process is capable of producing every batch of the final product meeting the endotoxin limits, and provide validation evidence for that sampling plan and test; and\n    (b) provide a scientifically sound justification that addresses the risks for not testing every batch.","sortOrder":0}],"analysis":{"kimi_summary":{"content_quality":"ok","complexity_score":3,"scope_assessment":{"changed":false,"description":"The legislation maintains its original narrow scope. It was clearly intended from inception to establish specific endotoxin contamination standards for high-risk medical devices, and it does exactly that without expanding into broader quality management, manufacturing process controls, or other safety domains. The device categories in section 5 align precisely with the stated purpose of addressing endotoxin risks in critical implantable and invasive devices."},"complexity_factors":["Only 7 defined terms in section 4, most referencing existing definitions in the parent Act or Regulations","Clear hierarchical structure with numbered sections and subsections, minimal nesting (maximum 2 levels)","No cross-references to external legislation beyond the parent Act and Regulations","Straightforward conditional logic: two main categories of devices (general vs. intraocular) with specific numeric thresholds","Single exception pathway (subsection 6(3)) for assembled components with justification requirement","Total length is approximately 2 pages with simple, technical-but-readable prose","No delegated legislation-making powers or sunset clauses"],"plain_english_summary":"This law imposes strict endotoxin limits on high‑risk medical devices sold in Australia—targeting invasive, bloodstream/CSF‑contact and ocular devices and those labelled sterile/non‑pyrogenic—requiring most to meet ≤20 EU, cerebrospinal‑contact ≤2.15 EU, and eye‑contact ≤0.2 EU. Manufacturers must test each batch or adopt a scientifically justified sampling plan, and may use validated alternative methods. It ensures devices meet recognised safety standards to prevent fever, shock and death from bacterial endotoxin exposure."},"flash_summary_failed":{"failed":true,"reason":"Unauthenticated. Configure AI_GATEWAY_API_KEY or use a provider module. Learn more: https://ai-sdk.dev/unauthenticated-ai-gateway","source":"analysis-cron"},"flash_summary":{"complexity_score":5,"scope_assessment":{"changed":false,"description":"The Order itself establishes endotoxin limits and testing requirements for the listed kinds of medical devices under the Minister's power; it does not indicate a change from any prior stated intent or expand beyond its stated categories. No text in this Order purports to widen or narrow the statutory scope beyond setting these device standards under the Act."},"complexity_factors":["Multiple device categories with different numerical endotoxin limits, including stricter limits for CSF contact and intraocular devices (sections 5, 6(1)-(2)).","Cumulative endotoxin accounting where multiple components are assembled into a final product, requiring component-level limits to meet overall thresholds (section 6(3)).","Testing method requirement referencing a default standard or validated alternative, plus mandatory scientific justification and validation evidence for alternatives (section 7(1)-(2)).","Batch testing required 'on every batch' unless impractical, with prescribed validation and sampling-plan obligations when full batch testing is not done (section 7(3)-(4)).","Cross-references to the Therapeutic Goods Act and Regulations and treatment as a medical device standard under the Act, creating interaction with broader regulatory obligations (preamble, sections 1–4).","Defined terms (e.g. final product, endotoxin, manufacturer) that affect application and compliance scope (section 4).","Discretion and evidentiary requirements on manufacturers to justify departures from prescriptive testing (sections 7(2), 7(4)), which create potential administrative and technical compliance burdens."],"plain_english_summary":"This Order sets mandatory endotoxin limits and testing/validation requirements for specified sterile medical devices (implantable devices, devices contacting cardiovascular/lymphatic/CSF systems, intraocular devices, and other sterile non‑pyrogenic devices). Manufacturers must ensure final products meet numeric endotoxin thresholds and use validated bacterial endotoxin test methods.\n\nIt affects device manufacturers and testing laboratories by imposing testing frequency, validation and sampling‑plan obligations, shifting quality‑assurance and compliance costs onto manufacturers and altering production and testing practices to control endotoxin risk."}},"importantCases":[],"_links":{"self":"/api/acts/medical-device-standards-order-endotoxin-requirements-for-medical-devices-2018","history":"/api/acts/medical-device-standards-order-endotoxin-requirements-for-medical-devices-2018/history","analysis":"/api/acts/medical-device-standards-order-endotoxin-requirements-for-medical-devices-2018/analysis","conflicts":"/api/acts/medical-device-standards-order-endotoxin-requirements-for-medical-devices-2018/conflicts","importantCases":"/api/acts/medical-device-standards-order-endotoxin-requirements-for-medical-devices-2018/important-cases","documents":"/api/acts/medical-device-standards-order-endotoxin-requirements-for-medical-devices-2018/documents"}}